Repligen (RGEN) to Release Earnings on Wednesday

Repligen (NASDAQ:RGEN) is expected to be issuing its quarterly earnings data before the market opens on Wednesday, February 19th. Analysts expect the company to announce earnings of $0.41 per share and revenue of $167.58 million for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

Repligen Price Performance

Shares of Repligen stock opened at $146.92 on Tuesday. Repligen has a 52-week low of $113.50 and a 52-week high of $211.13. The stock has a market capitalization of $8.23 billion, a price-to-earnings ratio of -397.07, a price-to-earnings-growth ratio of 4.54 and a beta of 0.99. The company has a fifty day moving average of $155.26 and a 200-day moving average of $148.82. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.76 and a current ratio of 10.44.

Wall Street Analyst Weigh In

RGEN has been the subject of several research reports. Wolfe Research initiated coverage on shares of Repligen in a report on Thursday, November 14th. They issued a “peer perform” rating for the company. Canaccord Genuity Group initiated coverage on shares of Repligen in a research note on Tuesday, December 17th. They set a “hold” rating and a $165.00 price objective for the company. TD Cowen began coverage on shares of Repligen in a research note on Monday, February 10th. They set a “buy” rating and a $200.00 price objective for the company. StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a report on Friday, January 3rd. Finally, HC Wainwright dropped their price objective on shares of Repligen from $240.00 to $180.00 and set a “buy” rating on the stock in a report on Thursday, January 23rd. Six equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $182.91.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.